Drug news

Alcon acquires North American rights to Finafloxacin for Ear Infections.

Read time: 1 mins

Last updated:28th Jan 2012

Published:28th Jan 2012

Source: Pharmawand

Alcon has acquired from Singapore company, MerLion Pharma, exclusive rights in North America to an otic formulation of finafloxacin for use in ear infections, including acute otitis externa (outer ear and ear canal) and acute otitis media (middle ear) infections.Drug is in Phase II.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity

Eli Lilly and Company announced positive topline results of the SURMOUNT-OSA phase III clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints

2 mins

Drug news

Topline results from phase II PRECEDENT study of dalzanemdor (SAGE 718) in the treatment of mild cognitive impairment in Parkinson’s disease

Sage Therapeutics, Inc. announced topline results from PRECEDENT, a double-blind, placebo-controlled Phase II study of the investigational oral medicine dalzanemdor (SAGE-718) in people with mild cognitive impairment (MCI) in Parkinson’s Disease (PD)

1 min

Drug news

Positive phase III topline results from Study 501 evaluating lumateperone as adjunctive therapy in patients with major depressive disorder

Intra-Cellular Therapies, Inc. a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announced positive topline results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)

2 min

See all news